MicroRNAs in sickle cell disease: A comprehensive review

被引:0
作者
Gupta, Parul [1 ]
Kumar, Ravindra [1 ,2 ]
机构
[1] ICMR Natl Inst Res Tribal Hlth, Nagpur Rd, Jabalpur, Madhya Pradesh, India
[2] Acad Sci & Innovat Res, Ghaziabad, Uttar Pradesh, India
关键词
Sickle cell disease; miRNA; Malaria; Vaso-occlusive crisis; Fetal hemoglobin; FETAL-HEMOGLOBIN INDUCTION; ANEMIA; VASOOCCLUSION; HYDROXYUREA; CRISPR-CAS9; MALARIA;
D O I
10.1016/j.gene.2025.149470
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Sickle cell disease (SCD) is a multifactorial disease characterized by a high incidence of morbidity and mortality due to chronic hemolysis, inflammation and oxidative stress. Recent studies have highlighted the crucial role of microRNAs (miRNAs) in regulating key pathophysiological processes in SCD, including high levels of fetal hemoglobin production, and reduction in inflammation and cellular adhesion. This comprehensive review discusses the current understanding of miRNAs in SCD, including their potential as biomarkers and therapeutic targets. Furthermore, despite substantial evidences indicating that malaria exacerbates SCD, the review will explore the complex interplay between miRNAs and SCD, with a focus on the exacerbating effects of malaria on SCD severity. Understanding the complex interplay between miRNAs and SCD may lead to the development of novel therapeutic interventions aimed at ameliorating disease severity and improving patient outcomes. Future prospects, challenges and safety concerns related to miRNA-based therapies, highlighting the need for further research.
引用
收藏
页数:6
相关论文
共 59 条
[1]   Fetal hemoglobin in sickle cell anemia [J].
Akinsheye, Idowu ;
Alsultan, Abdulrahman ;
Solovieff, Nadia ;
Duyen Ngo ;
Baldwin, Clinton T. ;
Sebastiani, Paola ;
Chui, David H. K. ;
Steinberg, Martin H. .
BLOOD, 2011, 118 (01) :19-27
[2]   Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo [J].
Anastasiadou, Eleni ;
Seto, Anita G. ;
Beatty, Xuan ;
Hermreck, Melanie ;
Gilles, Maud-Emmanuelle ;
Stroopinsky, Dina ;
Pinter-Brown, Lauren C. ;
Pestano, Linda ;
Marchese, Cinzia ;
Avigan, David ;
Trivedi, Pankaj ;
Escolar, Diana M. ;
Jackson, Aimee L. ;
Slack, Frank J. .
CLINICAL CANCER RESEARCH, 2021, 27 (04) :1139-1149
[3]   Sickle cell vaso-occlusion [J].
Chiang, EY ;
Frenette, PS .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2005, 19 (05) :771-+
[4]  
Christopher Ajay Francis, 2016, Perspect Clin Res, V7, P68, DOI 10.4103/2229-3485.179431
[5]   miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis [J].
Condrat, Carmen Elena ;
Thompson, Dana Claudia ;
Barbu, Madalina Gabriela ;
Bugnar, Oana Larisa ;
Boboc, Andreea ;
Cretoiu, Dragos ;
Suciu, Nicolae ;
Cretoiu, Sanda Maria ;
Voinea, Silviu Cristian .
CELLS, 2020, 9 (02)
[6]   Inflammation in sickle cell disease [J].
Conran, Nicola ;
Belcher, John D. .
CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2018, 68 (2-3) :263-299
[7]   The Role of miRNAs as Therapeutic Tools in Sickle Cell Disease [J].
Cyrus, Cyril .
MEDICINA-LITHUANIA, 2021, 57 (10)
[8]   Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease [J].
Darshana, Thamal ;
Rees, David ;
Premawardhena, Anuja .
ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
[9]   CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease [J].
Demirci, Selami ;
Leonard, Alexis ;
Essawi, Khaled ;
Tisdale, John F. .
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2021, 23 :276-285
[10]   Gene therapy for sickle cell disease: An update [J].
Demirci, Selami ;
Uchida, Naoya ;
Tisdale, John F. .
CYTOTHERAPY, 2018, 20 (07) :899-910